Boston Scientific (BSX) is trading sharply lower after the company reduced its 2026 outlook, with the guidance cut overshadowing better-than-expected first-quarter results. The revised forecast lowered expectations for full-year profitability and trimmed the company’s organic revenue growth view, reviving concerns that underlying trends in coming quarters may be softer than investors had been pricing in. (investing.com)

In its Q1 2026 update, Boston Scientific posted $5.203 billion in net sales and reported year-over-year growth, but investors focused on the forward view rather than the backward-looking beat. The guidance reset has become a focal point for the stock over the past week, with market commentary attributing renewed downside to the lowered 2026 expectations. (morningstar.com)

Adding to the negative tone, investors have also been seeing repeated alerts about a securities class-action process tied to an earlier period, with a lead-plaintiff motion deadline set for May 4, 2026. While these notices don’t change day-to-day operations, they can weigh on sentiment when combined with a high-profile guidance reduction and heightened scrutiny on disclosure around growth expectations. (globenewswire.com)

Traders will be watching for follow-through estimate cuts and additional price-target revisions after the company’s updated 2026 framework. The next catalyst is whether management provides more clarity on what drove the reduced outlook—particularly whether the change reflects near-term demand dynamics, competitive pressures, or conservatism after the stock’s recent volatility. (investing.com)